p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

[1]  Zhen Wang,et al.  The association of miR34b/c and TP53 gene polymorphisms with Wilms tumor risk in Chinese children , 2020, Bioscience reports.

[2]  Victoria Sanz-Moreno,et al.  Faculty Opinions recommendation of QuPath: Open source software for digital pathology image analysis. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  Hanlee P. Ji,et al.  Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer , 2019, Scientific Reports.

[4]  N. Cho,et al.  Prognostic implications and interaction of L1 methylation and p53 expression statuses in advanced gastric cancer , 2019, Clinical Epigenetics.

[5]  Taesung Park,et al.  Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer , 2017, Cancer.

[6]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[7]  Seung-Yong Jeong,et al.  Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system , 2017, British Journal of Cancer.

[8]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[9]  D. Sargent,et al.  Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Muller,et al.  Novel targets and interaction partners of mutant p53 Gain-Of-Function. , 2016, Biochemical Society transactions.

[11]  Jeong Eon Lee,et al.  Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[12]  Cheryl H. Arrowsmith,et al.  Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth , 2015, Nature.

[13]  Chuanhui Xu,et al.  Prognostic Significance of Cyclin D1 Expression in Colorectal Cancer: A Meta-Analysis of Observational Studies , 2014, PloS one.

[14]  Xiaolin Zhou,et al.  Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations , 2014, Scientific Reports.

[15]  A. D. Dei Tos,et al.  A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. , 2012, Cancer cell.

[16]  Reiko Nishihara,et al.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer , 2012, International journal of cancer.

[17]  M. Heymans,et al.  Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer , 2012, Annals of Surgical Oncology.

[18]  I. Shih,et al.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis , 2011, Modern Pathology.

[19]  N. Cho,et al.  Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status , 2011, Virchows Archiv.

[20]  J. Mariadason,et al.  Biomarkers of 5-FU response in colon cancer , 2011, Cancer biology & therapy.

[21]  A. V. D. van den Brule,et al.  Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study , 2010, Cancer Chemotherapy and Pharmacology.

[22]  P. Validire,et al.  Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  V. Rotter,et al.  Mutant p53 gain-of-function in cancer. , 2010, Cold Spring Harbor perspectives in biology.

[24]  Shuji Ogino,et al.  p21 Expression in Colon Cancer and Modifying Effects of Patient Age and Body Mass Index on Prognosis , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[25]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Shuji Ogino,et al.  A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases , 2009, Clinical Cancer Research.

[27]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[28]  E. Ioachim.  Expression patterns of cyclins D1, E and cyclin‐dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki‐67 and PCNA) and clinicopathological features , 2008, International journal of clinical practice.

[29]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  R. Houlston,et al.  A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[32]  D. Kerr,et al.  Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[34]  H. Hass,et al.  Major prognostic impact of proapoptotic BAX protein expression in stage III (UICC) colon cancer treated by adjuvant chemotherapy , 2005 .

[35]  P. Novotny,et al.  Phase III double-blinded, randomized trial to evaluate the use of black cohosh in the treatment of hot flashes: A North Central Cancer Treatment Group study , 2005 .

[36]  Jian Kuang,et al.  Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities , 2005, Oncogene.

[37]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[38]  Marc Buyse,et al.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  B. Iacopetta.  TP53 mutation in colorectal cancer , 2003, Human mutation.

[40]  Norman Wolmark,et al.  Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  U. McDermott,et al.  Molecular and biochemical markers in colorectal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Diehl,et al.  p21Cip1 Promotes Cyclin D1 Nuclear Accumulation via Direct Inhibition of Nuclear Export* , 2002, The Journal of Biological Chemistry.

[43]  P J Catalano,et al.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.

[44]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[45]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[46]  H. Rockette,et al.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Bunn,et al.  Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. , 1998, Cancer research.

[48]  J N Weinstein,et al.  Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. , 1997, Cancer research.

[49]  J. Eshleman,et al.  Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[51]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[52]  V. Rotter,et al.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[53]  오현정.  P53 expression status is associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer. , 2019 .

[54]  D. Greenwood,et al.  Meta-analysis of Observational Studies , 2012 .

[55]  G. Pasz-Walczak,et al.  P21 (WAF1) expression in colorectal cancer: correlation with P53 and cyclin D1 expression, clinicopathological parameters and prognosis. , 2001, Pathology, research and practice.

[56]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  C. Tangen,et al.  A Southwest Oncology Group study , 1993 .